Blood Reviews
Volume 21, Issue 1 , Pages 21-36 , January 2007

The gray platelet syndrome: Clinical spectrum of the disease

References 

  1. Raccuglia G. Gray platelet syndrome: A variety of qualitative platelet disorder. Am J Med. 1971;51:818–828
  2. Hemmeler G. Thrombopathie familiale. Schweiz Med Wschr. 1958;88:1018–1019
  3. Libanska J, Falcao L, Gautier A, et al. Thrombocytopénie thrombocytopathique hypogranulaire héréditaire. Nouv Rev Fr Hématol. 1975;15:165–182
  4. Kurstjens R, Bolt C, Vossen M, Haanen C. Familiar thrombocytopathic thrombocytopenia. Br J Haematol. 1968;15:305–317
  5. Weiss HJ, Witte LD, Kaplan KL, et al. Heterogeneity in storage pool deficiency: Studies on granule-bound substances in 18 patients including variants deficient in α-granules, platelet factor 4, β-thromboglobulin, and platelet-derived growth factor. Blood. 1979;54:1296–1319
  6. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends in Immunology. 2004;25:489–495
  7. Gerrard JM, Phillips DR, Rao GHR, et al. Biochemical studies of two patients with the Gray Platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest. 1980;66:102–109
  8. Ginsberg MH, Wencel JD, White JG, Plow EF. Binding of fibronectin to α-granule-deficient platelets. J Cell Biol. 1983;92:571–573
  9. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective α-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol. 1981;102:10–19
  10. Levy-Toledano S, Caen JP, Breton-Gorius J, et al. Gray platelet syndrome; α-granule deficiency. J Lab Clin Med. 1981;98:831–848
  11. Nurden AT, Kunicki TJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the Gray Platelet syndrome. Blood. 1982;59:709–718
  12. Cramer EM, Vainchenker W, Vinci G, Guichard J, Breton-Gorius J. Gray platelet syndrome: Immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes. Blood. 1985;66:1309–1316
  13. Legrand C, Dubernard V, Kieffer N, Nurden AT. Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem. 1988;171:393–399
  14. Legrand C, Nurden AT. Studies on platelets of patients with inherited platelet disorders suggests that collagen-induced fibrinogen binding to membrane receptors requires secreted ADP but not released α-granule proteins. Thromb Haemost. 1985;54:603–606
  15. Baruch D, Lindhout T, Dupuy E, Caen JP. Thrombin-induced platelet factor Va formation in patients with a gray platelet syndrome. Thromb Haemost. 1987;58:768–771
  16. Berndt MC, Castaldi PA, Gordon S, Halley H, McPherson VJ. Morphological and biochemical confirmation of Gray platelet syndrome in two siblings. Aust NZ J Med. 1983;13:387–390
  17. Pfueller SL, David R. Platelet-associated immunoglobulins G, A and M are secreted during platelet activation: normal levels but defective secretion in grey platelet syndrome. Br J Haematol. 1988;68:215–241
  18. Pfueller SL, Howard MA, White JG, Menon C, Berry EW. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand facor in gray platelet syndrome. Thromb Haemost. 1987;58:1060–1063
  19. Kohler M, Hellstern P, Morgenstern E, et al. Gray platelet syndrome: Selective α-granule deficiency and thrombocytopenia due to increased platelet turnover. Blut. 1985;50:331–340
  20. Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in Gray platelet syndrome. Tokohu J Exp Med. 1986;149:425–436
  21. Mori K, Suzuki S, Sugai K, Akutsu Y, Ishikawa M, Sakai H. Morphological changes of platelets during the process of platelet aggregation in gray platelet syndrome. Tohoku J Exp Med. 1986;149:425–436
  22. Srivastava PC, Powling MJ, Nokes TJC, Patrick AD, Dawes J, Hardisty RM. Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin. Br J Haematol. 1987;65:441–446
  23. Vermylen C, Vermylen J, Hoet B, Scheiff JM, Ninane J, Cornu G. Grey platelet syndrome: Evidence for alpha-granule localization of the platelet plasminogen activator inhibitor-1 pool. Ped Hematol Oncol. 1991;8:111–120
  24. Clezardin P, Malaval L, Morel M-C, et al. Osteonectin is a α-granule component involved with thrombospondin in platelet aggregation. J Bone Min Resist. 1991;10:1059–1070
  25. Nurden P, Jandrot-Perrus M, Combrié R, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood. 2004;104:107–114
  26. Facon T, Goudemand J, Zandecki M, Estienne M-H, Fenaux P, Cosson A. Simultaneous occurrence of grey platelet syndrome and idiopathic pulmonary fibrosis: A role for abnormal megakaryocytes in the pathogenesis of pulmonary fibrosis. Br J Haematol. 1990;74:542–543
  27. Jantunen E, Hänninen A, Naukkarinen , Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: A case report with review of the literature. Am J Hematol. 1994;46:218–224
  28. Lages B, Sussman II, Levine SP, Coletti D, Weiss HJ. Platelet alpha granule deficiency associated with decreased P-selectin and selective impairment of thrombin-induced activation in a new patient with gray platelet syndrome (α-storage pool deficiency). J Lab Clin Med. 1997;129:364–375
  29. Falik-Zaccai TC, Anikster Y, Rivera CE, et al. A new genetic isolate of Gray platelet syndrome (GPS): Clinical, cellular and hematologic Studies. Mol Genet Metab. 2001;74:303–313
  30. White JG. Ultrastructural studies of the gray platelet syndrome. Am J Pathol. 1979;95:445–462
  31. White JG. Golgi complexes in hypogranular platelet syndromes. Platelets. 2005;16:51–60
  32. Morgenstern E, Patscheke H, Mathieu G. The origin of the membrane convolute in degranulating platelets. A comparative study of normal and “gray” platelets. Blut. 1990;60:15–22
  33. Enouf J, Lebret M, Bredoux R, Levy-Toledano S, Caen JP. Abnormal calcium transport into microsomes of grey platelet syndrome. Br J Haematol. 1987;65:437–440
  34. Enouf J, Corvazier E, Papp B, et al. Abnormal cAMP-induced phosphorylation of rap 1 protein in grey platelet syndrome platelets. Br J Haematol. 1994;86:338–346
  35. Rendu F, Marche P, Hovig T, et al. Abnormal phosphoinositide metabolism and protein phosphorylation in platelets from a patient with the grey platelet syndrome. Br J Haematol. 1987;67:199–206
  36. Mori K, Suzuki S, Akutsu Y, Ishikawa M, Sakai H. Gray platelet syndrome: relationship between morphological abnormality of the dense tubular system (DTS) and intracellular Ca2+ mobilization in the platelet. Acta Haematologica Japonica. 1989;52:1534–1541
  37. Arderiu G, Diaz-Ricart M, Domenech P, Escolar G, Ordinas A, Pujol-Moix N. Phosphotyrosine proteins in platelets from patients with storage pool disease: direct relation between granule defects and defective signal transduction. Haematologica. 2002;87:629–636
  38. Farndale RW, Sixma JJ, Barnes MJ, De Groot GP. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004;2:561–573
  39. Schmaier AH, Smith PM, Purdon AD, White JG, Colman RW. High molecular weight kininogen: localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood. 1986;67:119–130
  40. Hayward CPM, Weiss HJ, Lages B, et al. The storage defects in grey platelet syndrome and αδ-storage pool deficiency affect α-granule factor V and multimerin storage without altering their proteolytic processing. Br J Haematol. 2001;113:871–877
  41. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4–15
  42. Levine SP, Knieriem LK, Rager MA. Platelet factor 4 and the platelet secretd proteoglycan: immunologic characterization by crossed immunoelectrophoresis. Blood. 1990;75:902–910
  43. Sato T, Herman L, Chandler J, Stracher N, Detwiler T. Localization of a thrombin sensitive calcium pool in platelets. J Histochem Cytochem. 1975;23:103–106
  44. Disdier M, Morrissey JH, Fugate RD, Bainton DF, McEver RP. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol Biol Cell. 1992;3:309–321
  45. Rosa J-P, George JN, Bainton DF, Nurden AT, Caen JP, McEver RP. Gray platelet syndrome. Demonstration of alpha granule membranes that can fuse with the cell surface. J Clin Invest. 1987;80:1138–1146
  46. Gebrane-Younès J, Martin Cramer E, Orcel L, Caen JP. Gray platelet syndrome. Association between abnormal sorting in megakaryocyte α-granules and normal sorting in Weibel-Palade bodies of endothelial cells. J Clin Invest. 1993;92:3023–3028
  47. Drouin A, Favier R, Masse JM, et al. Newly recognized cellular abnormalities in the gray platelet syndrome. Blood. 2001;98:1382–1391
  48. White JG, Brunning RD. Neutrophils in the gray syndrome. Platelets. 2004;15:333–340
  49. Mitjavila MT, Vinci G, Villeval JL, et al. Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: its relationship to type beta tranforming growth factor (TGF-beta). J Cell Physiol. 1988;134:93–100
  50. Shehata M, Schwarzmeier JD, Hilgarth M, Hubmann R, Duechler M, Gisslinger H. TGF-β-1 induces bone marrow reticulin fibrosis in hairy cell leukemia. J Clin Invest. 2004;113:676–685
  51. Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic empiripolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice. Blood. 2004;104:3573–3580
  52. Schmitt A, Joualt H, Guichard J, Wendling F, Drouin A, Cramer E. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 2000;96:1342–1347
  53. Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002;100:3495–3503
  54. Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: Studies on one hundred six patients. Blood. 1987;70:620–623
  55. Gunay-Aygun M, Huizing M, Gahl WA. Molecular defects that affect platelet dense granules. Sem Thromb Hemost. 2004;30:537–547
  56. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost. 2005;3:1773–1782
  57. White JG. Medich giant platelet disorder: a unique α granule deficiency I: Structural abnormalities. Platelets. 2004;15:345–353
  58. Lo B, Li L, Gissen P, Christensen H, et al. Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet α-granule biogenesis. Blood. 2005;106:4159–4166
  59. Kahr WHA, Zheng S, Sheth P, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood. 2001;98:257–265
  60. Sheth PM, Kahr WHA, Haq MA, Veljkovic K, Rivard GE, Hayward CPM. Intracellular activation of the fibrinolytic cascade in the Quebec platelet disorder. Thromb Haemost. 2003;90:293–298
  61. Breton-Gorius J, Favier R, Guichard J, et al. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha granules and chromosome 11 deletion at 11q23. Blood. 1995;85:1805–1814
  62. Raslova H, Komura E, Le Couédic JP, et al. FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest. 2004;114:77–84
  63. Grossfeld PD, Mattina T, Lai Z, et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet. 2004;129A:51–61
  64. Jackson CW, Hutson NK, Steward SA, Saito N, Cramer EM. Platelets of the Wistar Furth rat have reduced levels of alpha-granule proteins. An animal model resembling gray platelet syndrome. J Clin Invest. 1991;87:1985–1991
  65. Pestina TI, Jackson CW, Stenberg PE. Abnormal subcellular distribution of myosin and talin in Wistar Furth rat platelets. Blood. 1995;85:2436–2446
  66. Stenberg PE, Barrie RJ, Pestina TI, et al. Prolonged bleeding time with defective platelet filopodia formation in the Wistar Furth rat. Blood. 1998;91:1599–1608
  67. Leven RM, Tablin F. Megakaryocyte and platelet ultrastructure in the Wistar Furth rat. Am J Pathol. 1988;132:417–426
  68. Swank RT, Jiang SY, Reddington M, et al. Inherited abnormalities in platelet organelles and platelet formation and associated altered expression of low molecular weight guanosine triphosphate-binding proteins in the mouse pigment mutant gunmetal. Blood. 1993;81:2626–2635
  69. Novak EK, Reddington M, Zhen L, et al. Inherited thrombocytopenia caused by reduced platelet production in mice with the gunmetal gene mutation. Blood. 1995;85:1781–1789
  70. Detter JC, Zhang Q, Mules EH, et al. Rab geranylgeranyl transferase α mutation in the gunmetal mouse reduces Rab prenylation and platelet synthesis. Proc Natl Acad Sci USA. 2000;97:4144–4149
  71. Novick P, Zerial M. The diversity of Rab proteins in vesicle transport. Curr Opin Cell Biol. 1997;9:496–504
  72. Zhang Q, Zhen L, Li W, et al. Cell-specific abnormal prenylation of Rab proteins in platelets and melanocytes of the gunmetal mouse. Br J Haematol. 2002;117:414–423
  73. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81:695–704
  74. Tiwari S, Italiano JE, Barral DC, et al. A role for Rab27b in NF-E2-dependent pathways of platelet formation. Blood. 2003;102:3970–3979
  75. Wilson SM, Yip R, Swing DA, et al. A mutation in Rab27a causes the vesicle transport defects observed in ashen mice. Proc Natl Acad Sci USA. 2000;87:7933–7938
  76. Novak EK, Gautam R, Reddington M, et al. The regulation of platelet dense granules by Rab27a in the ashen mouse, a model of Hermansky-Pudlak and Griscelli syndromes, is granule-specific and dependent on genetic background. Blood. 2002;100:128–135
  77. Kimura Y, Hart A, Hirashima M, et al. Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis. J Exp Med. 2002;195:941–952
  78. Benit L, Cramer EM, Masse JM, Dusanter-Fourt I, Favier R. Molecular study of the hematopoietic zinc finger gene in three unrelated families with gray platelet syndrome. J Thromb Haemost. 2005;3:2077–2080
  79. El.Golli N, Issertial O, Rosa J-P, Briquet-Laugier V. Evidence for α granule targeting sequence within platelet factor 4. J Biol Chem. 2005;280:30329–30335
  80. Zhu Y, Doray B, Possu A, Lehto VP, Kornfeld S. Binding of GGA2 to the lysosomal enzyme sorting motif of the mannose 6-phosphate receptor. Science. 2001;292:1716–1718
  81. Heijnen HF, Debili N, Vainchenker W, Breton-Gorius J, Geuze HJ, Sixma JJ. Multivesicular bodies are an intermediate stage in the formation of platelet α-granules. Blood. 1998;91:2313–2325
  82. Handagama PJ, Amrani DL, Shuman MA. Endocytosis of fibrinogen into hamster megakaryocyte α-granules is dependent on a dimeric γA conformation. Blood. 1995;85:1790–1795
  83. Klinger MH, Kluter H. Immunochemical colocalization of adhesive proteins with clathrin in human blood platelets: further evidence for coated vesicle-mediated transport of von Willebrand factor, fibrinogen and fibroncetin. Cell Tissue Res. 1995;279:453–457
  84. Nurden P, Poujol C, Durrieu-Jais C, et al. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood. 1999;93:1622–1633
  85. Gootenberg JE, Buchanan GR, Holtkamp CA, Casey CS. Severe hemorrhage in a patient with gray platelet syndrome. J Pediatr. 1986;109:1017–1019
  86. Berrebi A, Klepfish A, Varon D, et al. Gray platelet syndrome in the elderly. Am J Hematol. 1988;28:270–272
  87. Mues G, Wians FH, Kroft SH. EDTA-induced pseudo-gray platelet syndrome. Lab Med. 2001;32:332–335
  88. Cockbill SR, Burmester HBC, Heptinstall S. Pseudo grey platelet syndrome - grey platelets due to degranulation in blood collected into EDTA. Eur J Haematol. 1988;41:326–333
  89. Nurden P, George JN, Nurden AT. Inherited thrombocytopenias. In:  Colman RW,  Hirsh J,  Marder VJ,  Clowes AW,  George JN,  Goldhaber SZ editor. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 5th ed.. Philadelphia: Lippincott, Williams & Wilkins; 2006;p. 975–986
  90. Balduini CL, Cattaneo M, Fabris F, et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica. 2003;88:582–592
  91. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103:2096–2104
  92. Maguire PB, Moran N, Cagney G, Fitzgerald DJ. Application of proteomics to the study of platelet regulatory mechanisms. Trends Cardiovasc Med. 2004;14:207–220
  93. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001;86:23–33
  94. Hyman T, Huizing M, Blumberg PM, Falik-Zaccai TC, Anikster Y, Gahl WA. Use of a cDNA microarray to determine molecular mechanisms involved in grey platelet syndrome. Br J Haematol. 2003;122:142–149
  95. Li QX, Berndt MC, Bush AI, et al. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer’s disease in human platelet and brain: surface expression on the activated human platelet. Blood. 1994;84:133–142

PII: S0268-960X(05)00071-8

doi: 10.1016/j.blre.2005.12.003

Blood Reviews
Volume 21, Issue 1 , Pages 21-36 , January 2007

Article Tools

* Image Usage & Resolution